We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
MCRB

Price
0.72
Stock movement down
-0.03 (-4.53%)
Company name
Seres Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
123.10M
Ent værdi
211.10M
Pris/omsætning
1923.47
Pris/bog
5.15
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-18.22%
1 års afkast
-4.12%
3 års afkast
-53.54%
5 års afkast
-27.22%
10 års afkast
-
Senest opdateret: 2025-03-29

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UDBYTTE

MCRB betaler ikke udbytte

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning1923.47
Pris til egenkapital5.15
EV i forhold til salg3298.45

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier170.74M
EPS (TTM)-0.17
FCF pr. aktie (TTM)-1.04

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)64.00K
Bruttofortjeneste (TTM)-6.97M
Driftsindkomst (TTM)-141.70M
Nettoindkomst (TTM)-25.47M
EPS (TTM)-0.17
EPS (1 år frem)-0.41

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-10887.50%
Driftsmargin (TTM)-214748.36%
Fortjenstmargin (TTM)-39804.69%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter66.82M
Nettotilgodehavender0.00
Omsætningsaktiver i alt72.93M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr147.65M
Sum aktiver178.74M
Kreditor8.25M
Kortfristet/nuværende langsigtet gæld93.61M
Summen af kortfristede forpligtelser64.83M
Sum gæld154.82M
Aktionærernes egenkapital23.92M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)-157.23M
Investeringsudgifter (TTM)1.17M
Fri pengestrøm (TTM)-158.39M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-106.51%
Afkast af aktiver-14.25%
Afkast af investeret kapital-78.96%
Kontant afkast af investeret kapital-490.91%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning0.76
Daglig høj0.76
Daglig lav0.70
Daglig volumen709K
Højeste gennem alle tider49.49
1 års analytiker estimat3.87
Beta2.05
EPS (TTM)-0.17
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation6 May 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
MCRBS&P500
Nuværende prisfald fra top notering-98.54%-9.34%
Højeste prisfald-98.89%-56.47%
Højeste efterår dato15 Nov 20249 Mar 2009
Gennemsnitlig fald fra toppen-78.35%-11.07%
Gennemsnitlig tid til nyt højdepunkt351 days12 days
Maks. tid til nyt højdepunkt2403 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

OPLYSNINGER OM VIRKSOMHEDEN
MCRB (Seres Therapeutics Inc) company logo
Markedsværdi
123.10M
Markedsværdi kategori
Small-cap
Beskrivelse
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Personale
233
SEC-indsendelser
Adm. direktør
Eric D. Shaff
Land
USA
By
Cambridge
Aktietype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FORSTÅ FORRETNINGEN
Loading...